Oncologie

A Phase II of TAXOL® (Paclitaxel) over 3 hours in 192 platinum pre-treated patients for ovarian carcinoma

ECCO8 Lhomme C, Guastalla J-P, Dauplat J, Ferrera J-M, Oberling F, Vennin P, Pouillart P, Fumoleau P, Kerbrat P, Tubiana N, Heron J-F, Bugat R, Bachelot T, Schreinerova M, Fleury J, Namer M, Dufour P, Dieras V, Soler-Michel P, Pruvot I, Chanez M-A, Garet F, Chazard M, Pellae-Cosset B.

Vous souhaitez échanger
avec nos équipes

Contactez-nous

D’autres articles qui pourraient
vous intéresser

Risk Factors TFR CP-CML
Success stories - Oncologie - Facultatif

Identification of Individual Risk Factors for Treatment Free Remission (TFR) Failure in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients

Long-Term TKI Treatment Patterns
Success stories - Oncologie - Facultatif

Tyrosine Kinase Inhibitor (TKI) Treatment Patterns in 5,261 Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Patients in “Real-Life”

Use of Digital Health Technology to Enable Drug Development
Oncologie

Use of Digital Health Technology to Enable Drug Development